ALLMedicine™ Acquired Hemophilia Center
Research & Reviews 146 results
https://doi.org/10.1182/bloodadvances.2021004626
Blood Advances; Mingot-Castellano ME, Pardos-Gea J et. al.
Sep 15th, 2021 - The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed-up for a median time of 12 months. Patients were predominantly male (...
https://doi.org/10.1007/s12185-021-03212-9 10.1182/blood-2006-06-029850 10.1182/blood-2012-02-408930 10.1002/9780470757260.ch16 10.1016/S0950-3536(98)80049-8 10.1186/1756-0500-3-161 10.1111/hae.12138 10.2491/jjsth.19.140 10.1111/bjh.12091 10.1055/s-0038-1653759 10.1111/j.1365-2516.2008.01924.x 10.1007/s12185-019-02674-2 10.2491/jjsth.29.251 10.1111/j.1365-2516.2008.01785.x 10.26420/annhematoloncol.2017.1173 10.2169/internalmedicine.9150-17 10.1007/s00277-012-1485-3 10.1007/s12185-020-02983-x 10.1111/jth.13304 10.1055/s-0039-1692427 10.1182/bloodadvances.2017011536 10.1182/blood-2014-09-598268 10.1182/blood.V89.10.3663 10.1016/S0049-3848(00)00418-7 10.1111/j.1538-7836.2004.00802.x 10.1182/blood-2016-11-751347 10.1182/blood-2016-02-701805 10.1111/ejh.13249
International Journal of Hematology; Ieko M, Ohmura K et. al.
Sep 4th, 2021 - Coagulation factor inhibitors (CFIs) sometimes cause fatal bleeding conditions. Determination of an inhibitor titer (INH-titer) using the Bethesda method is essential for diagnosing diseases associated with CFIs and examining the effects of immuno...
https://doi.org/10.1111/jth.15515
Journal of Thrombosis and Haemostasis : JTH; Bonnefoy A, Merlen C et. al.
Aug 30th, 2021 - Acquired hemophilia A (AHA) is a potentially life-threatening bleeding disorder caused by factor VIII (FVIII) autoantibodies, involving various immunoglobulin (Ig) isotypes and IgG subclasses. We analyzed the profile of Ig against FVIII in patient...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294921
Medicine Wang LY, Shen Y et. al.
Aug 17th, 2021 - Poor availability and a lack of affordability of bypassing agents (recombinant activated factor VII and activated prothrombin complex concentrate) in west China prompted us to investigate an alternative cost-effective combination therapy. We aimed...
https://doi.org/10.1055/a-1579-5396
Thrombosis and Haemostasis; Farley S, Ousley R et. al.
Aug 6th, 2021 - Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A.|2021|Farley S,Ousley R,Van Wagoner N,Bril F,|
Drugs 7 results see all →
News 14 results
https://www.mdedge.com/internalmedicine/article/209872/bleeding-disorders/new-consensus-recommendations-bleeding-acquired?channel=39313
Caleb Rans
Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.
https://www.mdedge.com/ccjm/article/205517/hematology/unusual-cause-bruising/page/0/1?channel=50
Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.
https://www.mdedge.com/hematology-oncology/article/201468/bleeding-disorders/fviii/w-ratio-may-help-predict-relapse?channel=27970
Caleb Rans
May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans
Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.
https://www.mdedge.com/hematology-oncology/article/184636/thrombosis/chmp-recommends-change-eptacog-alfa
HT Staff
Oct 20th, 2018 - Photo by Bill Branson Vials of drug The European Medicine’s Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of the marketing authorization for the recombinant factor VIIa product eptacog alfa (N.
